Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer | Synapse
June 3, 2024Open Access
Supplementary Figure S1 from Preclinical Efficacy of a PSMA-Targeted Actinium-225 Conjugate (225Ac-Macropa-Pelgifatamab): A Targeted Alpha Therapy for Prostate Cancer
Puntos clave
Los puntos clave no están disponibles para este artículo en este momento.
Resumen
Figure S1. 225Ac-pelgi induces the phosphorylation of DNA damage markers in LNCaP, C4-2, and 22Rv1 prostate cancer cells